Pentoxifylline
Pentoxifylline structure
|
Common Name | Pentoxifylline | ||
|---|---|---|---|---|
| CAS Number | 6493-05-6 | Molecular Weight | 278.307 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 531.3±56.0 °C at 760 mmHg | |
| Molecular Formula | C13H18N4O3 | Melting Point | 98-100°C | |
| MSDS | Chinese USA | Flash Point | 275.1±31.8 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Modulation of cytochrome P450 2A5 activity by lipopolysaccharide: low-dose effects and non-monotonic dose-response relationship.
PLoS ONE 10(1) , e0117842, (2015) Mouse cytochrome P450 (CYP) 2A5 is induced by inflammatory conditions and infectious diseases that down-regulate the expression and activity of most other CYP isoforms. Enhanced oxidative stress and nuclear factor (erythroid 2-related factor) 2 (Nrf2) transcr... |
|
|
Plasma matrix metalloproteinase activity in horses after intravenous infusion of lipopolysaccharide and treatment with matrix metalloproteinase inhibitors.
Am. J. Vet. Res. 74(3) , 473-80, (2013) To establish an in vivo method for matrix metalloproteinase (MMP)-2 and MMP-9 induction in horses via IV administration of lipopolysaccharide (LPS) and to evaluate the ability of doxycycline, oxytetracycline, flunixin meglumine, and pentoxifylline to inhibit ... |
|
|
Pentoxifylline for slow to resolve hepatopulmonary syndrome post liver transplantation: helpful or unnecessary?
Acta Gastroenterol. Belg. 76(1) , 70-1, (2013)
|
|
|
[Current approach to therapy for male infertility in patients with varicocele].
Ter. Arkh. 84(10) , 56-61, (2012) To improve the results of treatment for male infertility in patients with varicocele and to evaluate the efficiency of microsurgical varicocelectomy performed by the same surgeon in a large group of patients.1127 infertile males aged 22 to 52 years (mean 29.6... |
|
|
Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line
Biomed. Pharmacother. 66(8) , 617-26, (2012) Melanoma is the most common malignant skin cancer, appears indestructible and is notoriously resistant to all current modalities of cancer treatment strategies. Pentoxifylline (PTX), a non-specific phosphodiesterase inhibitor, has shown to have radiosensitizi... |
|
|
Pentoxifylline for treating venous leg ulcers.
Cochrane Database Syst. Rev. 12 , CD001733, (2012) Healing of venous leg ulcers is improved by the use of compression bandaging but some venous ulcers remain unhealed, and some people are unsuitable for compression therapy. Pentoxifylline, a drug which helps blood flow, has been used to treat venous leg ulcer... |
|
|
Alcoholic hepatitis: diagnosis and management in 2012.
Expert Rev. Gastroenterol. Hepatol. 6(6) , 695-710, (2012) Alcoholic hepatitis is a severe form of alcohol-related liver injury and one of the most frequent liver presentations seen by acute medical services. The condition typically affects young and middle-aged adults who present with jaundice and coagulopathy. Many... |
|
|
Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation.
J. Clin. Pharmacol. 53(1) , 51-7, (2013) Pentoxifylline (PTX) is extensively metabolized in the body, and all its 3 plasma metabolites (M1, M4, M5) are pharmacologically active. The authors evaluated the pharmacokinetics of PTX and its metabolites in 20 patients with chronic heart failure (CHF). Ele... |
|
|
Pentoxifylline improves cutaneous wound healing in streptozotocin-induced diabetic rats.
Eur. J. Pharmacol. 700(1-3) , 165-72, (2013) Worldwide, 15% of the 200 million diabetics suffer from diabetic wounds. In 1997, the cost for amputation of toes and limbs that resulted from infected diabetic foot ulcers ranged from $25,000-$40,000 per incident. Increasing numbers of research have shown th... |
|
|
Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial.
Clin. Drug Investig. 33(3) , 215-22, (2013) Membranous glomerulonephritis (MGN) may cause proteinuria as the main complication and is a strong risk factor for end-stage renal disease. Current therapeutic regimens provide only partial renoprotection. Data derived from both animal and human studies provi... |